{
  "0EH.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Toleranzia AB",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TOLERANZIA AB",
    "state": null,
    "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.",
    "website": "http://www.toleranzia.com",
    "zipcode": "411 26"
  },
  "40M.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nanexa AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NANEXA AB",
    "state": null,
    "summary": "Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.",
    "website": "http://www.nanexa.com",
    "zipcode": "75450"
  },
  "5J2.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Gabather AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GABATHER AB (PUBL) SK-,44",
    "state": null,
    "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in MalmÃ¶, Sweden.",
    "website": "http://www.gabather.com",
    "zipcode": "211 20"
  },
  "6FN.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Klaria Pharma Holding AB (publ.)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KLARIA PHARMA HOLDING AB",
    "state": null,
    "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.",
    "website": "http://www.klaria.com",
    "zipcode": "754 50"
  },
  "AC6.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AlzeCure Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALZECURE PHARMA AB",
    "state": null,
    "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.",
    "website": "http://www.alzecurepharma.se",
    "zipcode": "141 57"
  },
  "ALZCUR.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AlzeCure Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AlzeCure Pharma AB",
    "state": null,
    "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.",
    "website": "http://www.alzecurepharma.se",
    "zipcode": "141 57"
  },
  "B6E.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedish Orphan Biovitrum AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SWEDISH ORPHAN BIOVIT.SK1",
    "state": null,
    "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.",
    "website": "http://www.sobi.com",
    "zipcode": "112 76"
  },
  "BGAIF": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOGAIA AG",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BGL.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOGAIA AB  B  SK 1",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BIOG-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BioGaia AB ser. B",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BIOGY": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOGAIA AG",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BIOVF": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedish Orphan Biovitrum AB (publ)",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SWEDISH ORPHAN BIOVITRUM AB",
    "state": null,
    "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.",
    "website": "http://www.sobi.com",
    "zipcode": "112 76"
  },
  "C5G.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Orexo AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OREXO AB  SK-,40",
    "state": null,
    "summary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.orexo.com",
    "zipcode": "754 50"
  },
  "CALT": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Calliditas Therapeutics AB",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "CALTX.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Calliditas Therapeutics AB",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a novel oral formulation of budesonide potent local immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "CLTEF": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CALLIDITAS THERAPEUTICS AB",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a novel oral formulation of budesonide potent local immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "EN9.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Enzymatica AB",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ENZYMATICA AB",
    "state": null,
    "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of illness. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; ViruProtect name in Austria and Belgium; ColdGuard name in South Africa; Zerinol Virus Defense in Italy; and Psysiomer Stop Virus in France. It also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden.",
    "website": "http://www.enzymatica.se",
    "zipcode": "223 70"
  },
  "ENZY.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Enzymatica AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Enzymatica AB",
    "state": null,
    "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of illness. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; ViruProtect name in Austria and Belgium; ColdGuard name in South Africa; Zerinol Virus Defense in Italy; and Psysiomer Stop Virus in France. It also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden.",
    "website": "http://www.enzymatica.se",
    "zipcode": "223 70"
  },
  "ERMA.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Enorama Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Enorama Pharma AB",
    "state": null,
    "summary": "Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in MalmÃ¶, Sweden.",
    "website": "http://www.enorama.se",
    "zipcode": null
  },
  "GABA.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Gabather AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Gabather AB",
    "state": null,
    "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in MalmÃ¶, Sweden.",
    "website": "http://www.gabather.com",
    "zipcode": "211 20"
  },
  "KA6N.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Karo Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KARO PHARMA AB  O.N.",
    "state": null,
    "summary": "Karo Pharma AB (publ) develops and markets prescription drugs, over-the-counter products, medical devices, and hospital supply products for pharmacies and the health care sectors in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. It offers dermatology products under the Decubal, Fungobase, indy beauty, Lucobase, Mildison, OLIVA, PoxClin, and PROPYLESS brands; intimate care products under the HemoClin, Multi-Gyn, Multi-Mam, Pevaryl, and Scheriproct brand names; and foot care products under the CCS, Cortimyk, Footner, Nailner, Pevaryl, and wortie brands. The company also provides pain, cough, cold products under the Bronkyl, Dolerin, Ibux, Mollipect, Nazamer, nozoil, Paracet, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Selexid brands; and wellness products under the Flux, AllÃ©vo, Dosett, Dax, antibac, BAMSE, Betavivo, and Lactocare brands. It sells its products to pharmacies and retailers through direct sales organisations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is based in Stockholm, Sweden.",
    "website": "http://www.karopharma.com",
    "zipcode": "111 22"
  },
  "KARO.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Karo Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Karo Pharma AB",
    "state": null,
    "summary": "Karo Pharma AB (publ) develops and markets prescription drugs, over-the-counter products, medical devices, and hospital supply products for pharmacies and the health care sectors in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. It offers dermatology products under the Decubal, Fungobase, indy beauty, Lucobase, Mildison, OLIVA, PoxClin, and PROPYLESS brands; intimate care products under the HemoClin, Multi-Gyn, Multi-Mam, Pevaryl, and Scheriproct brand names; and foot care products under the CCS, Cortimyk, Footner, Nailner, Pevaryl, and wortie brands. The company also provides pain, cough, cold products under the Bronkyl, Dolerin, Ibux, Mollipect, Nazamer, nozoil, Paracet, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Selexid brands; and wellness products under the Flux, AllÃ©vo, Dosett, Dax, antibac, BAMSE, Betavivo, and Lactocare brands. It sells its products to pharmacies and retailers through direct sales organisations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is based in Stockholm, Sweden.",
    "website": "http://www.karopharma.com",
    "zipcode": "111 22"
  },
  "KLAR.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Klaria Pharma Holding AB (publ.)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Klaria Pharma Holding AB",
    "state": null,
    "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.",
    "website": "http://www.klaria.com",
    "zipcode": "754 50"
  },
  "LC8A.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CALLIDITAS THERAP. AD 1/2",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a novel oral formulation of budesonide potent local immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "MB8A.F": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Moberg Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MOBERG PHARMA AB",
    "state": null,
    "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.",
    "website": "http://www.mobergpharma.se",
    "zipcode": "167 51"
  },
  "MOB.ST": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Moberg Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Moberg Pharma AB",
    "state": null,
    "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.",
    "website": "http://www.mobergpharma.se",
    "zipcode": "167 51"
  },
  "NANEXA.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nanexa AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Nanexa AB",
    "state": null,
    "summary": "Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.",
    "website": "http://www.nanexa.com",
    "zipcode": "75450"
  },
  "OASM.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Oasmia Pharmaceutical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Oasmia Pharmaceutical AB",
    "state": null,
    "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel that has completed pre-clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company also provides combination therapies, such as XR-19 for various forms of cancer, including ovarian, first-line breast, prostate, and lung cancer. In addition, its animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.oasmia.com",
    "zipcode": "752 28"
  },
  "OASMY": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Oasmia Pharmaceutical AB (publ)",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OASMIA PHARMACEUTICAL AB SPON A",
    "state": null,
    "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel that has completed pre-clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company also provides combination therapies, such as XR-19 for various forms of cancer, including ovarian, first-line breast, prostate, and lung cancer. In addition, its animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.oasmia.com",
    "zipcode": "752 28"
  },
  "ORX.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Orexo AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Orexo AB",
    "state": null,
    "summary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.orexo.com",
    "zipcode": "754 50"
  },
  "ORXOY": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Orexo AB (publ)",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OREXO AB",
    "state": null,
    "summary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.orexo.com",
    "zipcode": "754 50"
  },
  "PROB.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Probi AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Probi AB",
    "state": null,
    "summary": "Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. It conducts research primarily in the fields of gastrointestinal and immune health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. The company provides dietary supplement, and food and beverage products in the form of capsules, tablets, chewable tablets, spheres, fast melt sticks, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. It sells its products approximately in 40 countries worldwide. Probi AB (publ) has a collaboration with Ãrebro University for research into exploration of novel, needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian female population. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.",
    "website": "http://www.probi.com",
    "zipcode": "223 70"
  },
  "RLS.ST": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "RLS Global AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "RLS Global AB",
    "state": null,
    "summary": "RLS Global AB (publ), a medical technology company, develops and sells products for the treatment of diseases in wound and dental care in Sweden. Its products include ChloraSolv that is used for the treatment of chronic foot and leg ulcers for diabetic patients; and CariSolv, a gel used for treating caries. The company was founded in 1996 and is based in MÃ¶lndal, Sweden.",
    "website": "http://rls.global",
    "zipcode": "431 53"
  },
  "SECARE.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedencare AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Swedencare AB",
    "state": null,
    "summary": "Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProDen PlaqueOff dental bites, a pet dental product; ProDen PlaqueOff powder cat; ProDen PlaqueOff dental bones for dogs; ProDen PlaqueOff mini dental care bones, a chewy bone for smaller dogs; and ProDen PlaqueOff soft chews for dogs and cats. The company also provides dietary supplements for cats, dogs, and horses under the NutriScience brand, such as Glucosamine and Stomax used to renew joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid for joints and mobility; KalmAid, which helps to calm nervous dogs; and OmegaAid and RevitalAid, a feed supplement used for healthy skin and coat. In addition, it develops and manufactures equine supplements, including Gastrocare used to relieve gastric pain and improve appetite; Equine Gold, which helps horse to thrive; ArthriAid used to aid horse's own natural manufacture of cartilage; and AnxiKalm, a supplement to calm excitable horses. Further, the company provides ProDen PlaqueOff teeth and gums, a natural food supplement to enhance dental hygiene and prevent tartar buildup for human. It distributes its products through pharmacies, veterinary clinics, pet shops, animal hospital, and online. Swedencare AB (publ) was incorporated in 1993 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.swedencare.se",
    "zipcode": "205 12"
  },
  "SOBI.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedish Orphan Biovitrum AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Swedish Orphan Biovitrum AB",
    "state": null,
    "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.",
    "website": "http://www.sobi.com",
    "zipcode": "112 76"
  },
  "TOL.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Toleranzia AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Toleranzia AB",
    "state": null,
    "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.",
    "website": "http://www.toleranzia.com",
    "zipcode": "411 26"
  }
}
